Sichuan Kelun Pharmaceutical stock
002422.SZSHZSichuan Kelun Pharmaceutical Co., Ltd. Class A, HealthcareISIN CNE100000PW7
70Score 70 out of 100, Strong
Price and trend
87 / 100
Price history
+31% in one yearThe chart shows daily closes over 16 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 15% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 52).
The price is 15% below its 52-week high. Largest decline in 16 years: 59% (May 2018 to April 2022).
Chart figures for advanced users
- SMA 50$6.18
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.68
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)52
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.32
- The lowest closing price of the last twelve months.
- Resistance$7.70
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Sichuan Kelun Pharmaceutical Co., Ltd. Class A belongs to the Biotechnology industry (China) and, with a market value of $10.36B, is number 36 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.75B (down 15.9% year on year) and earnings of $255.14M (down 42%).
- For fiscal 2026, analysts expect on average revenue of $2.88B (up 4.7%) and adjusted earnings per share of $0.18.
Show more
- MEQIRI Score 70 out of 100 (Strong): rank 123 of 714 in Healthcare, median 53.
- The P/E is 35.1 (Biotechnology median 46.6, own median of recent years 25.8).
- Our model puts fair value at $7.34, with the price 11% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $1.65B, financial debt $648.66M.Stability 82
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 81
- Analysts expect strong earnings growthUp 21.7% a year through 2028 (estimates from 7 analysts).Growth 65
Weaknesses
- DilutionShare count up 11% since 2020.Capital allocation 46
- Volatile share priceVolatility 49% a year over the last 12 months.
Its standout strengths are momentum and technical analysis, while capital allocation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $5.24 and expensive above $12.23 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $6.03 (cash-flow model) and $8.64 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $6.89, at 7.8% it would be $7.94.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (46.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 0.3% on the twelve months before. Revenue has grown strongly since 2007, at around 13% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 46%, operating 11%, net 9%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 29 Apr 2027in 168 days
- Last reported
- 28 Oct 2026EPS reported $0.03 (expected $0.03)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 24 Oct 2026.
- Earnings per share
- $0.18−2.0%
- Revenue
- $2.88B−2.3%
- Earnings per share
- $0.23−3.0%
- Revenue
- $3.28B−2.4%
MEQIRI has stored the estimates since 24 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Sichuan Kelun Pharmaceutical
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Bio-TechneTECH $11.44B65
- BioMarin PharmaceuticalBMRN $11.3B50
- VaxcytePCVX $10.8B46
- Akeso9926.HK $10.58B32
- Spyre TherapeuticsSYRE $10.14B48
- TG TherapeuticsTGTX $10.07B65
- Genscript Biotech1548.HK $9.96B48
- Haisco Pharmaceutical Group002653.SZ $9.92B68
ETFs that hold Sichuan Kelun Pharmaceutical
Held by 37 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Xtrackers Harvest CSI300 UCITS ETF 1DRQFI | 0.23% | 0.65% | €251.46M |
| Xtrackers Harvest CSI A500 UCITS ETF 1DAH50 | 0.21% | 0.65% | €10.8M |
| iShares MSCI China A UCITS ETF36BZ | 0.17% | 0.40% | €1.79B |
Show 5 more
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.05% | 0.30% | €134.65M |
| Amundi MSCI China ESG Selection Extra UCITS ETF DistLHKG | 0.05% | 0.65% | €473.19M |
| WisdomTree Emerging Markets ex-State Owned Enterprises UCITS ETF AccumUSDXSOE | 0.04% | 0.32% | €17.98M |
| iShares MSCI China UCITS ETFICGA | 0.03% | 0.28% | €2.22B |
| Franklin FTSE China UCITS ETFFLXC | 0.02% | 0.19% | €1.3B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CN¥6.6707)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong since 7 Nov 2026, previously Neutral
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.